UBS Group
GNOM icon

UBS Group’s Global X Genomics & Biotechnology ETF GNOM Stock Holding History

UBS Group’s Portfolio GNOM Stock Details GNOM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$465K Sell
10,626
-3,101
-23% -$143K ﹤0.01% 6132
2025
Q4 		$624K Sell
13,727
-2,557
-16% -$113K ﹤0.01% 5951
2025
Q3 		$632K Buy
16,284
+1,084
+7% +$39.3K ﹤0.01% 5911
2025
Q2 		$513K Sell
15,200
-3,465
-19% -$110K ﹤0.01% 5984
2025
Q1 		$594K Sell
18,665
-2,396
-11% -$90.9K ﹤0.01% 5714
2024
Q4 		$818K Sell
21,061
-14
-0.1% -$588 ﹤0.01% 5466
2024
Q3 		$948K Sell
21,075
-1,925
-8% -$86.1K ﹤0.01% 4697
2024
Q2 		$960K Sell
23,000
-811
-3% -$33.9K ﹤0.01% 4458
2024
Q1 		$1.08M Sell
23,811
-654
-3% -$29.8K ﹤0.01% 4538
2023
Q4 		$1.13M Buy
24,465
+647
+3% +$26.4K ﹤0.01% 4391
2023
Q3 		$969K Sell
23,818
-1,946
-8% -$88.6K ﹤0.01% 4097
2023
Q2 		$1.25M Sell
25,764
-447
-2% -$22.4K ﹤0.01% 4017
2023
Q1 		$1.29M Sell
26,211
-1,087
-4% -$55.9K ﹤0.01% 3873
2022
Q4 		$1.38M Sell
27,298
-7,508
-22% -$387K ﹤0.01% 3763
2022
Q3 		$1.75M Sell
34,806
-6,116
-15% -$345K ﹤0.01% 3279
2022
Q2 		$2M Sell
40,922
-66,573
-62% -$3.38M ﹤0.01% 3149
2022
Q1 		$6.46M Sell
107,495
-56,913
-35% -$3.59M ﹤0.01% 2294
2021
Q4 		$13.1M Sell
164,408
-13,928
-8% -$1.17M ﹤0.01% 1915
2021
Q3 		$15.8M Buy
178,336
+4,244
+2% +$398K 0.01% 1683
2021
Q2 		$17.3M Sell
174,092
-14,565
-8% -$1.29M 0.01% 1605
2021
Q1 		$17M Buy
188,657
+54,603
+41% +$5.39M 0.01% 1552
2020
Q4 		$12.7M Buy
134,054
+28,091
+27% +$2.35M ﹤0.01% 1677
2020
Q3 		$7.62M Buy
105,963
+36,878
+53% +$2.64M ﹤0.01% 1844
2020
Q2 		$4.85M Buy
69,085
+54,029
+359% +$3.36M ﹤0.01% 2072
2020
Q1 		$750K Buy
15,056
+14,202
+1,663% +$822K ﹤0.01% 3604
2019
Q4 		$53K Buy
+854
New +$48.9K ﹤0.01% 6318

Other funds holding GNOM

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
OAM
Oppenheimer Asset Management New York $8.76B AUM 23.12% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
USCWA
U.S. Capital Wealth Advisors Austin, Texas $3.98B AUM 22.36% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
AA
Armis Advisers Atlanta, Georgia $1.09B AUM 22.88% 1-Year Est. Return
CFD
Creative Financial Designs Kokomo, Indiana $1.65B AUM 15.6% 1-Year Est. Return
SWA
Sightline Wealth Advisors Groton, Connecticut $236M AUM 12.89% 1-Year Est. Return

UBS Group's GNOM Position: Q1 2026 in Review

UBS Group reduced its Global X Genomics & Biotechnology ETF (GNOM) stake by 23% in Q1 2026, selling an estimated $143K and leaving 10,626 shares worth $465K. The position accounts for ﹤0.01% of the portfolio, ranked #6132.

UBS Group first reported a position in GNOM in Q4 2019 and has held it in 26 quarters since. The position peaked at $17.3M in Q2 2021. 40 funds tracked by Wall St. Rank hold GNOM as of Q1 2026.

  • UBS Group held 10,626 shares of Global X Genomics & Biotechnology ETF worth $465K as of Q1 2026.
  • UBS Group sold 3,101 Global X Genomics & Biotechnology ETF shares in Q1 2026, an estimated $143K.
  • Global X Genomics & Biotechnology ETF made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6132 holding.
  • UBS Group first reported a position in Global X Genomics & Biotechnology ETF in Q4 2019 and has held it in 26 quarters since.
  • UBS Group's Global X Genomics & Biotechnology ETF position peaked at $17.3M in Q2 2021.
  • 40 funds tracked by Wall St. Rank held Global X Genomics & Biotechnology ETF as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.